Results of a randomized trial of prophylactic chemotherapy in T3-T4 breast cancer patients previously treated by radiotherapy. 1978

B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
December 1985, Wiener medizinische Wochenschrift (1946),
B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
May 2002, Clinical breast cancer,
B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
January 2021, Integrative cancer therapies,
B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
March 1985, The British journal of surgery,
B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
April 2016, Anticancer research,
B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
January 2003, Tumori,
B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
October 2009, Breast cancer research and treatment,
B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
June 2011, American journal of clinical oncology,
B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
January 2002, International journal of radiation oncology, biology, physics,
B Serrou, and H Sancho-Garnier, and P Cappelaere, and R Plagne, and R Metz, and M Schneider, and P Chollet, and M Namer, and H Pujol, and J Gary-Bobo, and G Meyer, and G Mathé
January 2007, Journal of vascular surgery,
Copied contents to your clipboard!